Moderna (NASDAQ:MRNA) Stock Rating Upgraded by Hsbc Global Res

Moderna (NASDAQ:MRNA) was upgraded by stock analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

MRNA has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. TD Cowen cut their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Barclays decreased their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Finally, Bank of America cut their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $84.00.

Moderna Stock Performance

NASDAQ:MRNA opened at $37.29 on Monday. The stock has a market capitalization of $14.35 billion, a P/E ratio of -6.59 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna has a 12-month low of $35.80 and a 12-month high of $170.47. The stock has a 50-day moving average price of $57.82 and a 200 day moving average price of $96.07.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm earned ($1.39) EPS. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. Equities research analysts forecast that Moderna will post -9.43 EPS for the current fiscal year.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 2,930 shares of company stock valued at $217,170 over the last 90 days. 15.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. O Shaughnessy Asset Management LLC boosted its stake in Moderna by 40.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 10,869 shares of the company’s stock worth $1,158,000 after buying an additional 3,148 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in shares of Moderna by 307.7% in the 1st quarter. UniSuper Management Pty Ltd now owns 13,158 shares of the company’s stock valued at $1,402,000 after purchasing an additional 9,931 shares during the period. Bessemer Group Inc. lifted its stake in Moderna by 4.0% in the first quarter. Bessemer Group Inc. now owns 7,258 shares of the company’s stock valued at $774,000 after buying an additional 276 shares during the period. Lake Street Advisors Group LLC bought a new position in Moderna during the 1st quarter worth approximately $398,000. Finally, Crewe Advisors LLC bought a new position in shares of Moderna during the first quarter worth $167,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.